Answers are grounded in this paper and cite their sources.
Low aqueous solubility remains a major challenge in oral drug development, affecting about 40% of marketed drugs and up to 90% of pipeline compounds. Spray drying to form amorphous solid dispersions (ASDs) is widely used to enhance the solubility of Biopharmaceutics Classification System Class II and IV drugs by increasing thermodynamic solubility and inhibiting recrystallization. However, ASD development is complex, requiring careful polymer selection, an understanding of drug–polymer interactions, and control of process parameters and stability. Quality by Design, as outlined in ICH Q8(R2), provides a structured framework that links the Quality Target Product Profile to critical quality attributes, material attributes, and process parameters within a defined design space. This review presents an engineering-focused perspective on spray-dried ASD development, covering material thermodynamics, drying mechanisms, and process–property relationships, as well as solid-state characterization, scale-up, and process analytical technology to support robust and scalable manufacturing.
No takes yet. Share an insight, caveat, or question.
Gundeti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: